CytOSorb TreatMent Of Critically Ill PatientS Registry (COSMOS)

September 10, 2025 updated by: CytoSorbents, Inc

CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
3000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Austria
      • Klagenfurt, Austria, 9020
        • Recruiting
        • Klinikum Klagenfurt Am Worthersee
        • Principal Investigator:
          • Markus Köstenberger, Dr.
      • Vienna, Austria, 1090
        • Recruiting
        • Medizinische Universität Wien
        • Principal Investigator:
          • Martin Bernardi, ap. Prof. Priv.-Doz. Dr. Dr.
  • Germany
      • Aachen, Germany, 52074
        • Recruiting
        • Universitätsklinikum Aachen
        • Principal Investigator:
          • Philipp Hohlstein, MD
      • Bad Oeynhausen, Germany, 32545
        • Recruiting
        • Herz- und Diabeteszentrum Nordrhein-Westfalen
        • Principal Investigator:
          • Thomas Kirschning, MD
      • Bochum, Germany, 44789
        • Recruiting
        • Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil Bochum
        • Principal Investigator:
          • Nathalie Malewicz-Oeck, MD
      • Bochum, Germany, 44791
        • Recruiting
        • Katholisches Klinikum Bochum, St. Josef-Hospital
        • Principal Investigator:
          • Martin Bellgardt, MD, PD
      • Essen, Germany, 45147
        • Recruiting
        • Universitätsklinikum Essen, Medizinische Intensivtherapie
        • Principal Investigator:
          • Bartosz Tyczynski, MD
      • Essen, Germany, 45147
        • Recruiting
        • Universitätsklinikum Essen, Nephrologie
        • Principal Investigator:
          • Kristin Schönfelder, MD
      • Essen, Germany, 45147
        • Recruiting
        • Universitätsklinikum Essen, Thorax- und Kardiovaskuläre Chirurgie
        • Principal Investigator:
          • Matthias Thielmann, MD, Prof
      • Göttingen, Germany, 37075
        • Recruiting
        • Universitätsmedizin Göttingen, Herzzentrum Göttingen
        • Principal Investigator:
          • Aschraf El-Essawi, MD, PD
      • Göttingen, Germany, 37075
        • Recruiting
        • Universitätsmedizin Göttingen, Allgemein-, Viszeral- und Kinderchirurgie
        • Principal Investigator:
          • Thorsten Perl, MD, PD
      • Herford, Germany, 32049
        • Recruiting
        • Klinikum Herford
        • Principal Investigator:
          • Dietrich Henzler, MD, Prof
      • Jena, Germany, 07747
        • Recruiting
        • Universitatsklinikum Jena
        • Principal Investigator:
          • Christian Schulze, MD, Prof
      • Kassel, Germany, 34125
        • Withdrawn
        • Klinikum Kassel
      • Marburg, Germany, 35043
        • Recruiting
        • Universitätsklinikum Marburg
        • Principal Investigator:
          • Julian Kreutz, MD
      • Mönchengladbach, Germany, 41063
        • Terminated
        • Kliniken Maria Hilf
      • München, Germany, 80636
        • Recruiting
        • Deutsches Herzzentrum München
        • Principal Investigator:
          • Thomas Günther, MD, PD
      • München, Germany
        • Recruiting
        • LMU Klinikum München
        • Principal Investigator:
          • Christina Scharf-Janßen, MD, PD
      • Oldenburg, Germany, 26133
        • Recruiting
        • Klinikum Oldenburg
        • Principal Investigator:
          • Martin Tholl, MD
      • Wiesbaden, Germany, 65199
        • Recruiting
        • Helios Dr. Horst Schmidt Kliniken Wiesbaden
        • Principal Investigator:
          • Moritz Unglaube, MD
  • Italy
      • Roma, Italy, 00165
        • Terminated
        • Ospedale Pediatrico Bambino Gesu
      • San Giovanni Rotondo, Italy, 71013
        • Recruiting
        • IRCCS Ospedale Casa Sollievo della Sofferenza
        • Principal Investigator:
          • Filippo Aucella, MD
  • Poland
      • Krakow, Poland, 30-688
        • Recruiting
        • SP ZOZ Szpital Uniwersytecki w Krakowie
        • Principal Investigator:
          • Anna Wrzosek, Dr.
      • Wroclaw, Poland, 50-556
        • Recruiting
        • Uniwersyteckim Spitalem Klinicznym im. Jana Mikulicza - Radeckiego we Wrocławiu
        • Principal Investigator:
          • Waldemar Goździk, Prof
  • Portugal
      • Coimbra, Portugal, 3004-561
        • Recruiting
        • Unidade Local De Saude De Coimbra E.P.E
        • Principal Investigator:
          • Ricardo André Baptista Patrício Silva Freitas, Dr.
      • Lisbon, Portugal
        • Recruiting
        • ULS São José, Hospital Curry Cabral
        • Principal Investigator:
          • Nuno Germano, MD
  • Spain
      • Huelva, Spain
        • Recruiting
        • Hospital Juan Ramón Jiménez
        • Principal Investigator:
          • Mario Márquez Fernández
    • Barcelona
      • Barcelona, Barcelona, Spain, 08035
        • Recruiting
        • Hospital Universitari Vall d'Hebron
        • Principal Investigator:
          • Ricard Ferrer Roca, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Critically ill patients receiving CytoSorb therapy

Description

Inclusion Criteria:

  1. Planned OR actual CytoSorb® 300 mL device utilization
  2. Informed consent for prospective registry participation

Exclusion Criteria:

  1. Use of the CytoSorb® 300 mL device for antithrombotic removal only
  2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only
  3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
ICU mortality
Time Frame: Through ICU discharge or date of death, whichever comes first [on average 7 days]
Through ICU discharge or date of death, whichever comes first [on average 7 days]
In-hospital mortality
Time Frame: Through hospital discharge or date of death, whichever comes first [on average 14 days]
Through hospital discharge or date of death, whichever comes first [on average 14 days]

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
CytoSorbents, Inc

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Ricard Ferrer Roca, MD, Hospital Vall d'hebrón

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 22, 2022

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2032

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 1, 2032

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 23, 2021

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 23, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
December 6, 2021

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 11, 2025

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 10, 2025

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • O06

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings